Table 3.
Treatment with adefovir dipivoxil modulates clinical profiles of HBV patients.
| Parameters | 0 weeks | 12 weeks | 24 weeks |
|---|---|---|---|
| HBV DNA (log10 copies/mL) | |||
| Median (range) | 8,4 (5,7–9,8) | 3,5 (1,9–5,8)* | 2,5 (1,8–4,1)* |
| ALT (U/L) | |||
| Median (range) | 219 (12–914) | 45 (16–171)* | 24 (10–148)* |
| AST (U/L) | |||
| Median (range) | 117 (22–221) | 27 (18–123)* | 22 (16–54)* |
| HBsAg (IU/mL) | |||
| Median (range) | 4697,68 (1243,65–55925,04) | 3478,45 (890,34–17118,09) | 1729,56 (356,71–12315,86)* |
| HBsAb (mIU/mL) | |||
| Median (range) | 0,06 (0–3,71) | 0,4 (0–4,41) | 3,56 (0,52–8,56)* |
| HBeAg (S/CO) | |||
| Median (range) | 3233,3 (3,88–4094,10) | 539,62 (0,47–2345,67)* | 21,3535 (0,35–766,13)* |
| HBeAb (S/CO) | |||
| Median (range) | 16,74 (0,02–46,74) | 1,26 (0,01–35,67)* | 0,46 (0–16,23)* |
Normal values: ALT ≤ 40 IU/L; AST ≤ 40 IU/L; HBV DNA ≤ 3 log10 copies/mL.
∗ P< 0.05 patients after treatment with adefovir dipivoxil versus patients at baseline.